207 related articles for article (PubMed ID: 10799053)
1. Resistance of vaccinia virus to inactivation by solvent/detergent treatment of blood products.
Roberts P
Biologicals; 2000 Mar; 28(1):29-32. PubMed ID: 10799053
[TBL] [Abstract][Full Text] [Related]
2. Virus inactivation by solvent/detergent treatment using Triton X-100 in a high purity factor VIII.
Roberts PL
Biologicals; 2008 Sep; 36(5):330-5. PubMed ID: 18674928
[TBL] [Abstract][Full Text] [Related]
3. Virus inactivation in a factor VIII/VWF concentrate treated using a solvent/detergent procedure based on polysorbate 20.
Roberts PL; Lloyd D; Marshall PJ
Biologicals; 2009 Jan; 37(1):26-31. PubMed ID: 18848782
[TBL] [Abstract][Full Text] [Related]
4. A minipool process for solvent-detergent treatment of cryoprecipitate at blood centres using a disposable bag system.
Burnouf T; Goubran HA; Radosevich M; Sayed MA; Gorgy G; El-Ekiaby M
Vox Sang; 2006 Jul; 91(1):56-62. PubMed ID: 16756602
[TBL] [Abstract][Full Text] [Related]
5. A process for solvent/detergent treatment of plasma for transfusion at blood centers that use a disposable-bag system.
Burnouf T; Goubran HA; Radosevich M; Sayed MA; Gorgy G; El-Ekiaby M
Transfusion; 2006 Dec; 46(12):2100-8. PubMed ID: 17176321
[TBL] [Abstract][Full Text] [Related]
6. Sindbis virus as a tool for quality control of viral inactivation of heated and chemically treated plasma-derived products.
Espíndola OM; Belluci MS; Oliveira BC; Liberto MI; Cabral MC
J Virol Methods; 2006 Jun; 134(1-2):171-5. PubMed ID: 16507321
[TBL] [Abstract][Full Text] [Related]
7. Impact of Triton X-100 on alpha 2-antiplasmin (SERPINF2) activity in solvent/detergent-treated plasma.
Burnouf T; Goubran HA; Radosevich M; Sayed MA; Gorgy G; El-Ekiaby M
Biologicals; 2007 Oct; 35(4):349-53. PubMed ID: 17656111
[TBL] [Abstract][Full Text] [Related]
8. Inactivation of virus in intravenous immunoglobulin G using solvent/detergent treatment and pasteurization.
Aghaie A; Pourfatollah AA; Bathaie SZ; Moazzeni SM; Khorsand Mohammad Pour H; Sharifi Z
Hum Antibodies; 2008; 17(3-4):79-84. PubMed ID: 19029665
[TBL] [Abstract][Full Text] [Related]
9. Dengue virus inactivation by minipool TnBP/Triton X-45 treatment of plasma and cryoprecipitate.
Burnouf T; Chou ML; Cheng LH; Li ZR; Wu YW; El-Ekiaby M; Tsai KH
Vox Sang; 2013 Jan; 104(1):1-6. PubMed ID: 22758375
[TBL] [Abstract][Full Text] [Related]
10. Viral safety of solvent-detergent treated blood products.
Horowitz B; Prince AM; Horowitz MS; Watklevicz C
Dev Biol Stand; 1993; 81():147-61. PubMed ID: 8174797
[TBL] [Abstract][Full Text] [Related]
11. Viral safety of a new highly purified factor VIII (OCTATE).
Biesert L; Lemon S; Goudeau A; Suhartono H; Wang L; Brede HD
J Med Virol; 1996 Apr; 48(4):360-6. PubMed ID: 8699169
[TBL] [Abstract][Full Text] [Related]
12. Comparable virus inactivation by bovine or vegetable derived Tween 80 during solvent/detergent treatment.
Seitz H; Blümel J; Schmidt I; Willkommen H; Löwer J
Biologicals; 2002 Sep; 30(3):197-205. PubMed ID: 12217344
[TBL] [Abstract][Full Text] [Related]
13. Inactivation and clearance of viruses during the manufacture of high purity factor IX.
Johnston A; Macgregor A; Borovec S; Hattarki M; Stuckly K; Anderson D; Goss NH; Oates A; Uren E
Biologicals; 2000 Sep; 28(3):129-36. PubMed ID: 10964439
[TBL] [Abstract][Full Text] [Related]
14. Comparative removal of solvent and detergent viral inactivating agents from human intravenous immunoglobulin G preparations using SDR HyperD and C18 sorbents.
Burnouf T; Sayed MA; Radosevich M; El-Ekiaby M
Anal Biochem; 2009 Jun; 389(1):69-73. PubMed ID: 19303391
[TBL] [Abstract][Full Text] [Related]
15. Dry-heat treatment process for enhancing viral safety of an antihemophilic factor VIII concentrate prepared from human plasma.
Kim IS; Choi YW; Kang Y; Sung HM; Shin JS
J Microbiol Biotechnol; 2008 May; 18(5):997-1003. PubMed ID: 18633304
[TBL] [Abstract][Full Text] [Related]
16. [Evaluation of viral safety of a high-purity human factor VIII concentrate submitted to 2 specific virus inactivation treatments (FANDHI)].
Ristol P; Gensana M; Fernández J; Massot M; Biescas H; Darling A; Jorquera JI; Vericat F
Sangre (Barc); 1996 Apr; 41(2):131-6. PubMed ID: 9045353
[TBL] [Abstract][Full Text] [Related]
17. Solvent/detergent treatment of platelet concentrates enhances the release of growth factors.
Burnouf T; Tseng YH; Kuo YP; Su CY
Transfusion; 2008 Jun; 48(6):1090-8. PubMed ID: 18373502
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of inactivation of enveloped viruses by the biosurfactant surfactin from Bacillus subtilis.
Vollenbroich D; Ozel M; Vater J; Kamp RM; Pauli G
Biologicals; 1997 Sep; 25(3):289-97. PubMed ID: 9324997
[TBL] [Abstract][Full Text] [Related]
19. [Possibilities of virus inactivation of pooled fresh plasma with tri-n-butylphosphate (TNBP) detergents (SD procedure)].
Gürtler L
Infusionsther Transfusionsmed; 1994 Aug; 21 Suppl 1():77-9. PubMed ID: 8000260
[TBL] [Abstract][Full Text] [Related]
20. Robustness of solvent/detergent treatment of plasma derivatives: a data collection from Plasma Protein Therapeutics Association member companies.
Dichtelmüller HO; Biesert L; Fabbrizzi F; Gajardo R; Gröner A; von Hoegen I; Jorquera JI; Kempf C; Kreil TR; Pifat D; Osheroff W; Poelsler G
Transfusion; 2009 Sep; 49(9):1931-43. PubMed ID: 19497061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]